Sheldon L Bloch Net Worth

The estimated Net Worth of Sheldon L Bloch is at least $1.79 Million dollars as of 27 November 2006. Sheldon Bloch owns over 2,639 units of AMAG Pharmaceuticals stock worth over $1,744,450 and over the last 18 years Sheldon sold AMAG stock worth over $40,584.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Sheldon Bloch AMAG stock SEC Form 4 insiders trading

Sheldon has made over 3 trades of the AMAG Pharmaceuticals stock since 2006, according to the Form 4 filled with the SEC. Most recently Sheldon exercised 2,639 units of AMAG stock worth $108,621 on 27 November 2006.

The largest trade Sheldon's ever made was exercising 2,639 units of AMAG Pharmaceuticals stock on 27 November 2006 worth over $108,621. On average, Sheldon trades about 1,460 units every 19 days since 2006. As of 27 November 2006 Sheldon still owns at least 69,778 units of AMAG Pharmaceuticals stock.

You can see the complete history of Sheldon Bloch stock trades at the bottom of the page.

What's Sheldon Bloch's mailing address?

Sheldon's mailing address filed with the SEC is C/O ADVANCED MAGNETICS, INC., 125 CAMBRIDGEPARK DRIVE, 6TH FLOOR, CAMBRIDGE, MA, 02140.

Insiders trading at AMAG Pharmaceuticals

Over the last 18 years, insiders at AMAG Pharmaceuticals have traded over $162,079,471 worth of AMAG Pharmaceuticals stock and bought 3,622,220 units worth $65,172,892 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Partners Gp, L.L.C.... und Capital Management Lp Camber. On average, AMAG Pharmaceuticals executives and independent directors trade stock every 42 days with the average trade being worth of $2,148,850. The most recent stock trade was executed by Capital Management Lp Camber on 1 October 2020, trading 4,390,000 units of AMAG stock currently worth $59,572,300.

What does AMAG Pharmaceuticals do?

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.

Complete history of Sheldon Bloch stock trades at AMAG Pharmaceuticals

AMAG Pharmaceuticals executives and stock owners

AMAG Pharmaceuticals executives and other stock owners filed with the SEC include:

• Joseph Vittiglio,
  Executive Vice President, General Counsel, Corporate Secretary, Chief Business Officer
• Anthony Casciano,
  Chief Operating Officer, Executive Vice President and Chief Commercial Officer
• Gino Santini,
  Independent Chairman of the Board
• Kathrine O'Brien,
  Independent Director
• Anne Phillips,
  Independent Director
• Davey Scoon,
  Independent Director
• John Fallon,
  Independent Director
• James Sulat,
  Independent Director
• David Johnson,
  Independent Director
• Paul Fonteyne,
  Independent Director
• Linda Lennox,
  Vice President - Investor Relations and Corporate Communications
• Nancy Griffith,
  Vice President - Scientific Communications And Medical Operations
• Kelly Schick,
  Chief Human Resource Officer, Senior Vice President
• Brian Piekos,
  Chief Financial Officer
• Scott Myers,
  President, Chief Executive Officer, Director
• Barbara Deptula,
  Director
• Brian P Kelley,
  Director
• Lesley Russell,
  Director
• Robert J Perez,
  Director
• Edward H Myles,
  COO & CFO
• William K Heiden,
  President & CEO
• Nicholas Grund,
  Chief Commercial Officer
• Elizabeth Scott Bolgiano,
  Chief Human Resources Officer
• Partners Lp Caligan,
  10% owner
• Julie Krop,
  Chief Medical Officer
• James Alan Butcher,
  EVP, Chief Business Officer
• Capital Management Lp Camber,
  
• Capital, Llc Armistice Capi...,
  
• Kenneth H Wilson,
  SVP, Sales and Marketing
• Geoffrey Crouse,
  EVP
• Edward P. Jordan,
  SVP, Sales and Marketing
• Scott B Townsend,
  SVP, General Counsel
• Capital Partners Gp, L.L.C....,
  
• Steven Caffe,
  SVP, Ch. Dev. and Reg. Officer
• Ron Zwanziger,
  Director
• Michael Narachi,
  Director
• Sheldon L Bloch,
  Director
• Christopher G White,
  Chief Business Officer and SVP
• Jerome M Lewis,
  VP of Scientific Operations
• David Arkowitz,
  CFO & Chief Business Officer
• Jerome Goldstein,
  CEO and Treasurer
• Ricardo Zayas,
  Sr. Vice President, Operations
• Mark B Skaletsky,
  Director
• Silva Rajiv De,
  Director
• Gary J Zieziula,
  EVP, Chief Commercial Officer
• Michael D Loberg,
  Director
• Frank E Thomas,
  President & COO
• Michael N Avallone,
  VP-Finance and CFO
• Scott A Holmes,
  Chief Accounting Officer
• Joseph Vincent Bonventre,
  Director
• Brian Jg Pereira,
  President and CEO
• Greg Madison,
  EVP, Chief Commercial Officer
• Theodore I Steinman,
  Director
• Edward B Roberts,
  Director
• Timothy G Healey,
  SVP-Commercial Operations
• Lee F Md Ph D Allen,
  CMO & SVP Clinical Dev.
• Joseph L Farmer,
  Gen Counsel & VP Legal Affairs
• Louis Md Brenner,
  Senior Vice President